A Patient Died in BMS’s MS CAR-T Trial. No One Can Say Why.
A Phase 1 multiple sclerosis patient died 44 days after a zola-cel infusion. BMS says confounding factors prevent it...
A Phase 1 multiple sclerosis patient died 44 days after a zola-cel infusion. BMS says confounding factors prevent it...
NEJM's lentiviral in vivo CAR-T data in neurologic autoimmune disease is compelling, but the trial infrastructure to validate it...
A Nature Medicine RCT of allogeneic iPSC-derived cardiomyocytes in advanced ischemic heart failure just set the protocol bar for...
FDA cleared RiboX's RXIM002 IND for the first circular RNA-based in vivo CAR-T therapy — here's what it means...
A Nature Medicine phase 1 iPSC neural progenitor trial in subacute spinal cord injury shows how to build the...
ReMIND's multi-antigen T cell data in 25 pediatric CNS patients points to a regulatory inflection point sponsors haven't mapped...